Last updated: April 26, 2026
Israel IL183247: Scope, Claims, and Patent-Landscape Implications
What is IL183247 and what does it claim?
IL183247 is an Israeli patent publication/patent record with claims tied to a specific protected subject matter defined in its claim set. The record is referenced here only to the extent needed to support scope mapping to the competitive patent landscape.
Claim scope cannot be reproduced without the exact claim text from IL183247. Patent scope in Israel is claim-defined under local practice, and downstream landscape outcomes (design-arounds, freedom-to-operate, and likely injunction risk) depend on independent claim elements, claim numbering, claim dependencies, and any Markush alternatives. Without the actual IL183247 claim language, any “scope” summary would be structurally unverifiable.
How broad is IL183247’s legal scope (independent-claim lens)?
A usable scope assessment requires the independent claims’:
- Product or composition definition (active ingredient(s), salts, polymorphs, solvates, hydrates)
- Formulation parameters (dosage form, excipients, particle size, release profile, specs)
- Method definition (indications, patient population, dosing regimens, treatment steps)
- Structural and functional limitations (pharmacophore definitions, target binding, activity ranges)
- Markush breadth (alternative substituents, groups, or functional classes)
Those elements must be extracted verbatim from IL183247 to determine whether coverage is:
- Generic-compound level (active ingredient or salt class)
- Specific-form level (polymorph/solvate/hydrate or device-form)
- Use level (new indication, dosing regimen, patient selection)
- Process level (manufacturing method with narrow process parameters)
What dependent-claim hooks usually drive infringement risk in Israel?
Israel infringement analysis tracks claim coverage rather than marketing claims. For IL183247-type applications, infringement risk is commonly driven by:
- Salt/polymorph sub-claims (if independent claim is compound class, dependent claims narrow to a specific solid form; conversely, if independent is specific form, dependents add formulation and use)
- Dosage regimen sub-claims (stepwise dosing schedules, titration ranges, or monotherapy/combination timing)
- Combination claims (co-administration schedules and “in combination with” language)
- Therapeutic-use claims that tie to an indication and a biomarker-defined patient group
Without IL183247’s dependent claim text, it is not possible to map which of these hooks control scope and how competitors can design around.
Where does IL183247 sit in the Israeli patent landscape (families, priority chain, and regulatory relevance)?
A credible landscape for an Israeli patent requires at least:
- Patent family identification (INPADOC family, publication numbers, priority date, assignees)
- Status in Israel (granted vs pending, term adjustments, expiry)
- Relationship to regulatory exclusivity (data exclusivity, orphan, pediatric, SPC if applicable)
- Citations and exam record (if accessible via the record, and to detect likely validity chokepoints)
A landscape with actionable precision depends on the published bibliographic data tied to IL183247, including its publication number, application number, assignee, priority date(s), and claim set at publication/grant. Those fields are not present in the supplied input and cannot be reconstructed without the underlying IL183247 record.
What competitive patents likely cluster around IL183247 (mechanistic vs claim-type map)?
A landscape is typically organized in layers that reflect how competitors challenge scope:
Layer 1: Same active and solid-form / salt variants
- Same molecular entity, alternative salts
- Polymorphs, hydrates, solvates
- Crystalline vs amorphous forms
Layer 2: Same therapeutic concept, different dosing/regimens
- Different dosing schedules
- Monotherapy vs combination sequence/timing
- Patient selection (biomarkers, disease stage)
Layer 3: Same target, different chemistry class
- Next-generation analogs
- Re-engineered variants (prodrugs, ester forms)
Layer 4: Same indication, different formulation or delivery
- Controlled release profiles
- Device-based administration
A claim-type map is only accurate when tied to the IL183247 claim elements. Without the claim text, any list of “likely nearby patents” would be speculative.
What does the IL183247 scope imply for design-arounds?
Design-around strategies depend on which claim elements are doing the narrowing:
-
If IL183247 is compound-class based, design around typically targets:
- substitute the chemical core
- use a non-infringing salt/solvate/polymorph not covered by the claim definition
-
If IL183247 is solid-form/formulation based, design around typically targets:
- different crystalline form
- different excipient system
- different release profile or particle-size distribution
-
If IL183247 is use/dosing based, design around typically targets:
- alternative dosing regimen outside the claimed range
- different combination timing or absence of the co-administered partner
- different patient selection criteria
These pathways cannot be tied to IL183247 without the actual claim boundaries.
How to read IL183247’s claim structure to assess validity risk (practical litigation lens)
For Israeli pharma portfolios, validity risk typically concentrates on:
- Novelty (prior art disclosure of the same compound/form/use)
- Inventive step (combination of teachings or obviousness)
- Sufficiency (enablement and support for broad claims)
- Clarity (whether claim elements are definite and measurable)
A claims-to-validity mapping requires:
- the exact claim terms (including ranges and functional limitations)
- the priority and filing timeline
- the cited prior art in the application record
None of that is available in the prompt.
Key Takeaways
- IL183247’s scope and claim boundaries cannot be generated accurately from the provided input because the claim text and bibliographic record are not included.
- A claim-defined scope assessment for Israel depends on independent and dependent claim language, including any salt/polymorph/formulation, regimen, and combination limitations.
- An actionable patent landscape requires the IL183247 family identity, priority chain, and status fields, which are not present in the input.
FAQs
1) Can I rely on a summary of IL183247’s scope without the claim text?
No. In Israel, claim-defined scope determines infringement and validity outcomes.
2) What is the first step to map IL183247’s landscape risk?
Extract the independent claims and any dependent claim limitations that narrow compound form, dosage, use, or combination.
3) What claim features most often block generic or biosimilar-style entries?
Salt or solid-form limitations, dosing regimens with specific ranges, and combination-timing “in combination with” structures.
4) How does the patent family affect landscape outcomes in Israel?
Family scope drives which foreign filings survive and which equivalents in Israel are likely to be granted, enforceable, or expired.
5) What data fields are essential to build a litigation-grade landscape?
Claim text (publication and grant versions), priority chain, assignee, status in Israel, and family publication identifiers.
References
[1] Israel Patent Office. Patent records and publication information (IL183247).
